Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Form or Function: How Does Pink1 Deficiency Mar Mitochondria?
1 June 2009. Mutations in the PTEN-induced novel kinase 1 (Pink1) gene cause a recessive form of early-onset parkinsonism, and all the evidence points to mitochondria as the prime locus of the damage. From its first identification, Pink1 was found to be important at keeping a healthy electrical balance across the mitochondrial membrane (see ARF related news story and Valente et al., 2004). Further studies in fruit flies showed that Pink1 knockout results in severe swelling and disorganization of mitochondria. These morphological effects were attributed to a lack of normal mitochondrial fission, as expression of the fission-promoting GTPase dynamin-related protein 1 (Drp1) compensated for the loss of Pink1 (see Park et al., 2006; Clark et al., 2006; and ARF related news story on Yang et al., 2008 and ARF related news story on Poole et al., 2008).

But data are accumulating in support of the controversial idea that the target for Pink1’s attack may lie elsewhere, that is, not in mitochondrial fission/fusion dynamics but at the heart of mitochondrial function itself, in energy production. The latest installment comes from Mark Cookson and colleagues at the National Institutes of Health in Bethesda, Maryland. In a paper published May 27 in PLoS ONE, the researchers show that knocking out Pink1 in a human neuroblastoma cell line adversely affects mitochondrial membrane potential and renders cells more sensitive to mitochondrial toxins. That finding was expected. But the morphological changes in the mitochondria, and the role of Drp1, were exactly opposite to that seen in flies. The lack of Pink1 produced smaller, more fragmented organelles, and promoting fission by expressing of Drp1 exacerbated cell toxicity. The morphological effects resolved when the cells were treated with the phosphatase inhibitor FK506, which blocked dephosphorylation and activation of Drp1; however, FK506 was unable to restore the membrane potential. The new results echo recent work from Bart De Strooper’s lab that suggested Pink1 inhibits the respiratory chain at Complex I, resulting in energy-starved dysfunctional synapses. This effect occurred in the absence of morphological changes in the organelles (see ARF related news story).

Cookson explained his group’s results in terms of primary and secondary effects of Pink1 loss. “The important thing we see is that although we can use FK506 to rescue some of the morphological effects, the functional effects were still there. This says that there is an order to things; there are early first events and there are later secondary events. Our interpretation of our data is that what Pink1 is really doing is maintaining mitochondrial function. And when you see subtle morphological effects, or grossly distended mitochondria, or nothing at all, that’s probably because those changes are secondary.”

To look at the effects of Pink1 on mitochondria function and morphology in living cells, first authors Anna Sandebring and Kelly Thomas made human dopaminergic M17 cell lines that overexpressed Pink1 or Pink1 shRNAs, and imaged mitochondria by a variety of techniques. Consistent with previous work, overexpression of Pink1 protected cells from the mitochondrial toxin rotenone, while the knockdown showed more cell death and mitochondrial fragmentation after treatment. Without Pink1, mitochondria had lower membrane potential and exhibited subtle morphological changes. The mitochondria appeared “a bit shorter and more fragmented,” Cookson told ARF. “It was not a huge effect, but it let us go into the mechanism.”

The scientists next examined the effect of Drp1. Partial knockdown of Drp1 prevented mitochondrial fragmentation in Pink1-minus cells, whereas overexpression of Drp1 made it worse. The results indicate that lack of Pink1 renders mitochondria sensitive to Drp1-induced fission. This was associated with a loss of Drp1 phosphorylation and increased GTPase activity. At the same time, cellular activity of the calcium-dependent Drp1 phosphatase calcineurin increased. Treating cells with the calcineurin inhibitor FK506 restored Drp1 phosphorylation levels, decreased the number of truncated or fragmented mitochondria, and restored the pattern of normal mitochondrial connection. However, FK506 did not cure the lower membrane potential.

From these results, the authors propose a model where loss of Pink1 has as its primary effect a loss of mitochondrial membrane potential. As a result, cells not only accumulate more reactive oxygen species, but they also fail to buffer calcium effectively. Increased calcium could activate calcineurin, leading to dephosphorylation of Drp1 and increased mitochondrial fission. In another species or cell type or developmental stage, the result on mitochondrial morphology might differ, Cookson said, depending on the regulation of Drp1 or other downstream effectors. In some cases, as in Pink1 knockout mice, there may be no morphological changes at all (Gautier et al., 2008). Nonetheless, Cookson says the primary deficit—a loss of mitochondrial health—is conserved.

Support for this idea comes from another recent paper from the lab of Charleen Chu at the University of Pittsburgh (Dagda et al., 2009). In that work, Pink1 knockdown in a different neuronal cell line, SH-SY5Y, also caused mitochondrial fragmentation. The paper suggests a role for mitochondria turnover via autophagy, which was also stimulated by Pink1 knockdown. The destruction of (presumably unhealthy) mitochondria was protective for the cells, and was enhanced by overexpression of the parkin protein, which has been implicated in autophagy (Narendra et al., 2008). The finding that parkin can compensate for Pink1 deficiency matches genetic studies in Drosophila, and Cookson reports that his group has similar, unpublished results in their cell lines showing a conservation of parkin function.

“If you look across all these studies, the observation that’s most clear is that the mitochondria are not at their full potential,” Cookson said. “It’s the details that are not clear.” The biggest detail Cookson is eager to settle is what Pink1 actually phosphorylates. “All of the evidence so far is that the kinase does not act directly on any of these fusion or fission proteins, but we haven’t looked at all of them. There is some evidence that it might phosphorylate parkin (see Kim et al., 2008), but I don’t know if that’s been reproduced.”—Pat McCaffrey.

Reference:
Sandebring A, Thomas KJ, Beilina A, van der Brug1 M, Cleland MM, Ahmad R, Miller DW, Zambrano I, Cowburn RF, Behbahani H, Cedazo-Mínguez A, Cookson MR. Mitochondrial Alterations in PINK1 Deficient Cells Are Influenced by Calcineurin-Dependent Dephosphorylation of Dynamin-Related Protein 1. 2009 May 27. PLoS ONE4(5):e5701. Abstract

 
Comments on News and Primary Papers
  Comment by:  Bingwei Lu
Submitted 1 June 2009  |  Permalink Posted 1 June 2009

The key difference between this study and the previous Drosophila studies is that a transformed neuroblastoma cell line is used here, whereas previous studies looked at postmitotic neurons and muscle in an in-vivo setting using Pink1-null mutant animals. It is known that mitochondria in proliferating cells and differentiated cells are very different, both in terms of morphology and function. This may account for the different conclusions from these studies. Future studies using postmitotic neurons, preferably dopaminergic neurons from Pink1 knockout animals, will be required to make fair comparisons between the studies.

View all comments by Bingwei Lu

  Comment by:  Konstanze Winklhofer
Submitted 4 June 2009  |  Permalink Posted 4 June 2009

Accumulating evidence indicates that mitochondrial dysfunction is a key factor in the pathophysiology of Parkinson disease (PD). Inhibitors of complex I of the electron transport chain, such as MPTP and rotenone, can induce parkinsonism, and a decreased activity of complex I has indeed been detected in the substantia nigra of patients suffering from PD. Remarkably, the identification of genes associated with familial PD confirmed the crucial role of mitochondria for the integrity of dopaminergic neurons. One of the genes associated with autosomal-recessive PD encodes a bona fide mitochondrial protein, PINK1, a serine/threonine kinase that can protect cells against mitochondrial toxins.

In Drosophila melanogaster, loss of PINK1 function causes apoptotic flight muscle degeneration and defective spermatogenesis, and mitochondrial pathology is the earliest manifestation of these phenotypes (Clark et al., 2006; Park et al., 2006; Yang et al., 2006). PINK1 deficiency in flies can be rescued by increasing mitochondrial fission or decreasing fusion, leading to the conclusion...  Read more


  Primary Papers: Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1.

Comment by:  Vanessa Morais
Submitted 10 June 2009  |  Permalink Posted 10 June 2009

PINK1: Mitochondria bioenergetics dysfunction or deficient mitochondria dynamics? This question has raised some controversy in the Parkinson disease (PD) field in recent years. This matter is elegantly tackled in this paper from Sandebring and co-workers, where the authors attempt to address the underlying mechanism by which PINK1 influences mitochondrial morphology. In sum, they propose a mechanism where loss of PINK1 function causes decreased mitochondrial membrane potential (as has been previously reported by others), altering Ca2+ homeostasis, leading to the dephosphorylation of DRP1.

These findings link the mitochondrial functional deficits with secondary mitochondria morphology alterations. Moreover, their findings are in complete agreement with our own work, recently published in EMBO Molecular Medicine [1], where we also claim that mitochondrial dysfunction is upstream of mitochondrial morphological defects observed in PINK1-deficient models. In our work, we also observed a decrease in mitochondrial membrane potential in two PINK1-deficient animal models (mouse and...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad